25 April 2018 in Obesity and metabolism
РИРоманцова Татьяна Ивановна
Романцова Татьяна Ивановна
+17
The presented paper is a third revision of the clinical recommendations for the treatment of morbid obesity in adults. Morbid obesity is a condition with body mass index (BMI) 40 kg / m2 or a BMI 35 kg / m2 in the presence of serious complications associated with obesity. The recommendations provide data on the prevalence of obesity, its etiology and pathogenesis, as well as on associated complications. The necessary methods for laboratory and instrumental diagnosis of obesity are described in detail. In this revision of the recommendations, the staging of prescribing conservative and surgical methods for the treatment of obesity are determined. For the first time, a group of patients with obesity and type 2 diabetes mellitus is selected, in whom metabolic surgery allows a long-term improvement in the control of glycemia or remission of diabetes mellitus.
14 February 2021 in Obesity and metabolism
МЕЖДИСЦИПЛИНАРНЫЕ КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ «ЛЕЧЕНИЕ ОЖИРЕНИЯ И КОМОРБИДНЫХ ЗАБОЛЕВАНИЙ»
26 May 2021 in Eurasian heart journal
ЕВРАЗИЙСКИЕ РЕКОМЕНДАЦИИ ПО ПРОФИЛАКТИКЕ И ЛЕЧЕНИЮ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ У БОЛЬНЫХ С ДИАБЕТОМ И ПРЕДИАБЕТОМ (2021)
25 December 2019 in Obesity and metabolism
АВАдамская Любовь Владимировна
Адамская Любовь Владимировна
+1
The purpose of the article is to consider stress as one of the etiological factors of obesity and metabolic syndrome. The review discusses both endocrine and social aspects of stress as a syndrome of adaptation to the current situation in Russian society. It is emphasized that lifestyle factors contributing to the growth of overweight are gaining popularity in the society, and the high incidence of obesity is directly related to the level, quality and lifestyle of a modern man. Constant nervous tension, negative emotions, fear in conditions of abundance of food directly contributes to obesity, which is associated with a large number of other serious diseases. Chronic hyperactivation of the hypothalamic-pituitary-adrenal axis and chronic hypersecretion of cortisol, if persistence is not a purely physiological condition. Endocrine mechanisms mediating the development of metabolic disorders on the background of chronic stress include activation of the hypothalamic-pituitary-adrenal system, changes in eating behavior, hyper-production of glucagon and triglyceride accumulation in visceral fat depots. Processes and social changes occurring in modern society contribute to the construction of everyday socio-cultural environment characterized by increased stress. Chronic stress in combination with physical inactivity, the result of improper lifestyle of modern people, becomes an effective factor contributing to the spread among the population of Russia not only overweight, but also various forms of obesity. It is emphasized that at the state level there is an urgent need to adopt and implement effective programs and mechanisms to ensure the population meets modern requirements and environmental standards of healthy food, rationalization of food distribution among the population, the formation of a culture of food consumption, improving the quality of life of the population and the culture of a healthy lifestyle, teaching the population the correct stress-coping behavior.
9 August 2018 in Obesity Facts
GMGalina Afanasievna Melnichenko
Galina Afanasievna Melnichenko
MGMarina Olegovna Galieva
Objective: The aim of the study was to assess the effectiveness and safety of long-term sibutramine therapy in routine clinical practice. Methods: In total, 98,774 patients (82.3% women, 17.7% men) from 142 cities of the Russian Federation were enrolled in the PRIMAVERA program. The mean age of the patients was 39.39 ± 10.38 years, the mean body weight was 99.1 ± 14.28 kg, and the mean BMI was 35.7 ± 4.41 kg/m2. The duration of the sibutramine therapy was determined by physicians: 59.3% of patients took the drug for 6 months, the treatment course of 37.7% of patients was 12 months, and 3% of patients had treatment for 3 months. Results: The BMI reduction correlated with the treatment duration: 3.4 ± 1.53 kg/m2 after 3 months of therapy, 5.4 ± 2.22 kg/m2 after 6 months, and 7.2 ± 3.07 kg/m2 after 12 months. The body weight reduction after 3, 6 and 12 months of treatment was 9.5%, 15.1%, and 19.7%, respectively. The body weight loss associated with sibutramine treatment was accompanied by a slight decrease in blood pressure and did not lead to any significant increases of the heart rate. Conclusions: The results of the PRIMAVERA study confirmed the lack of increased risk of using sibutramine in routine clinical practice in patients without underlying cardiovascular disease and low rate of adverse events.
12 February 2021 in Problems of Endocrinology
Мониторинг эффективности программы профилактики заболеваний, связанных с дефицитом йода в Республике Тыва